FDA Extends Relutrigine NDA Review by Three Months
PRAX has more than doubled off its 52-week low of $37.19.
Summary
Praxis Precision Medicines announced a three-month extension of the FDA's review period for its relutrigine NDA, moving the PDUFA date to December 27, 2026, due to additional data submitted by the company.
Key Events · Product Development and Regulatory · PRAX
-
FDA Review Period Extended
The FDA extended the New Drug Application (NDA) review period for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) by three months.
-
New PDUFA Date Set
The PDUFA target action date for relutrigine is now December 27, 2026, delayed from the previous target of September 27, 2026.
-
Delay Due to Major Amendment
The extension follows the company's submission of additional sensitivity analyses of existing clinical data, which the FDA deemed a "major amendment" requiring more review time.
-
No Safety or Manufacturing Concerns
The FDA did not request any new clinical studies and did not cite any safety or manufacturing concerns regarding the relutrigine application.
Analysis · PRAX · Life Sciences
The FDA has extended the review period for Praxis Precision Medicines' New Drug Application (NDA) for relutrigine by three months, pushing the PDUFA date to December 27, 2026. This delay, triggered by the company's submission of additional sensitivity analyses deemed a "major amendment," introduces uncertainty and delays potential market entry for the drug. While no new clinical studies were requested and no safety or manufacturing concerns were cited, the extension is a setback for the company's pipeline progress.
At the time of this filing, PRAX was trading at $334.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $37.19 to $366.52. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.